Regulatory and ethical requirements in medical devices studies. France

Similar documents
Regulatory and ethical requirements in medical devices studies. Turkey

Regulatory and ethical requirements in medical devices studies. Italy

Regulatory and ethical requirements in medical device studies. Finland

Regulatory and ethical requirements in medical devices studies. Portugal

Regulatory and ethical requirements in medical device studies DENMARK

Regulatory and ethics bodies involved in approval process for trials. National Ethics Committee; Agency for Data Protection;

RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS

Regulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials

Health Registration and Training Center (HRTC/ENKK) , Mail: 1380 P.O. Box 1188 (Street: Zrinyi u. 3.

ANNEX. CHAPTER I General principles

Melbourne Health Guidelines Cover Sheet

Agence nationale de sécurité du médicament et des produits de santé (ANSM) ansm.sante.fr. 143/147 Boulevard Anatole France

Belgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be

Impact of Clinical EU Directive on the implementation of Early development studies in Europe

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs

State Institute for Control of Drugs-/ Státní ústav pro control léčiv (SÚKL) Regulatory and ethics bodies involved in approval process

Investigator Site File Index (Medical Devices)

1 PROCEDURE S OBJECT 2 PROCEDURE S SCOPE 3 RESPONSIBILITIES AND AUTHORITIES SOP FOR THE PHARMACOVIGILANCE OF THE CLINICAL TRIALS

Regulatory Newsletter January - March 2014

Clinical trials from CRA s point of view

Joint Research Office of Doncaster & Bassetlaw

Competent federal higher authority ("Bundesoberbehörde- BOB")

PROCEDURE OF FILING A REQUEST TO THE ETHICS COMMITEE OF THE UNIVERSITY CLINICAL CENTRE OF THE REPUBLIC OF SRPSKA

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Good Clinical Practice

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

Regulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

RSC/CT Det. no. 1/2013

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

Marie-Claire Rickard (RG and GCP Manager) Rachel Fay (RG and GCP Manager) Elizabeth Clough (R&D Governance Operations Manager)

NIS Considerations - France An overview of the considerations when conducting Noninterventional

Investigator Site File Index (CTIMP)

Standard Operating Procedure

Once notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.

Safety monitoring and reporting in clinical trials involving therapeutic goods

ETHICS COMMITTEE. TITLE: Safety Reporting STANDARD OPERATING PROCEDURE SOP006

Implementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

STANDARD OPERATING PROCEDURE

Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB! if CCMO acts as CA:

Standard Operating Procedure

The compassionate use of medicinal products. An example: the French ATU system. 0ff label use in France

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

SWOG

KLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6.

NIS Considerations - Bulgaria

VERSION: 21 st June Date of Publication: 15 th March C/ CAMPEZO, 1 EDIFICIO MADRID Tel.: Fax:

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

Research Ethics and Good Clinical Practice. Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London

STANDARD OPERATING PROCEDURE SOP 310

Recording, Managing and Reporting Adverse Events in the UK

MEDICINES CONTROL COUNCIL

3 RESPONSIBILITIES AND AUTHORITIES

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

GUIDELINES ON MEDICAL DEVICES

RESEARCH ETHICS BOARD GUIDELINES SUBMISSION OF RESEARCH PROJECTS

Meeting the Clinical Evaluation Requirements for CE Marking: Challenges for Innovative Start-ups Sarah Sorrel, MedPass International SAS

GUIDELINES ON MEDICAL DEVICES

PROPOSED DOCUMENT. Global Harmonization Task Force. Title: Reportable Events During Pre-Market Clinical Investigations

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

STUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION

Inspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

Guidance for applicants for ethics committee opinion on the conduct of a clinical trial of pharmaceuticals

Clinical Trials application process, legislation & guidelines

Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

N : AAHRPP-SOP-057 / REV 003 N ENGLISH VERSION :188

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

Life cycle of a clinical trial. IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed.

SERIOUS ADVERSE EVENTS

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA

The Victorian Streamlined Review Process and the National Mutual Acceptance (NMA) Streamlined Review Process for Clinical Trials

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

Highlights of the proposed Clinical Trials Regulation in Europe

Developing a European First-in-Human Study: Three Key Decisions

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

The installation and control in France of clinical trials relating to medical devices and in vitro diagnostic medical devices

Trial Master File. SOP No. SOP 7

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

N : CEHF-SOP-019 / REV003 N ENGLISH VERSION : 131

Course Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins

ICH GCP Revision and EU Clinical Trial Regulation

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

Standard Operating Procedure

Writing an Assessment Report

ORPHAN DESIGNATION BY THE EMA. Paillard Juliette M2 AREIPS 15/11/2016

Standard Operating Procedure Research Governance

Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting

Standard Operating Procedure. Safety Reporting for NuTH Sponsored, Medical Device Trials. SOP effective: 03 January 2018 Review date: 03 January 2020

Transcription:

Regulatory and ethical in medical devices studies France

SECTIONS A.Type of research

SECTIONS A.Type of research

We have differentiated 8 types of research: Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device Registries

SECTIONS A.Type of research

H. Data Ptotection Definitions in French law Ecept for «Observational studies with medical device», there is no French definition for studies with medical devices.

Conventions/guideline/laws to apply Declaration of Helsinki ICH Guideline of EMA European Directive 2011/20/EC (Only for studies with MD alone and observational studies) Law 2004-806 of 9 aout 2004 (completed by decree 2006-477 du 26 avril 2006) ISO 14155:2011 European Directive 90/385/EC and 93/42/EC

Acts to apply Data protection act (Ecept for registries) Genetical engineering act (Ecept for observational studies and registries)

SECTIONS A.Type of research

For all the type of studies in eception of registries, an insurance must be contracted. It has to cover: - Patients and /or healthy volunteers - Investigators - Sponsor It is not necessary that the insurance covers the manufacturer The compensation sums covered by the insurance depends of the protocol

SECTIONS A.Type of research

It is mandatory to have a sponsor in all the interventional studies: Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark

SECTIONS A.Type of research

No French specific /regulations for GCP training of the investigators

SECTIONS A.Type of research

French Competent : ANSM Agence national de sécurité du médicament et des produits de santé 143/147 Boulevard Anatole France 93285 Saint-Denis Cede +33 155 87 30 00 dedim.dm@ansm.sante.fr or EC.DM- COS@ansm.sante.fr

Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device Yes Approval No (if no risky eam)

Initial submission When a submission is required, the sponsor is responsible of it The submission to the French Competent is national: you only have to submit one dossier to the national competent authority The submission have to be: - by paper - or by email or CD-Rom English documents are accepted, at the eception of the protocol summary, the inform consent form and the information document for patient No submission fee

Initial submission In general, 60 days maimum to obtain approval Implicit approval after 60 days without questions No deadlines for submission, you can submit anytime No need to have some kind of representative or a legal entity in France to submit an application to the Competent if you are from the EU

F. Competant Initial submission Main documents required for submission: Submission letter Clinical Trial application form Clinical Investigation Plan/Protocol Clinical Investigation Plan/Protocol summary Copies of advertisement materials for research participants Investigator s brochure or CE certificate Instruction for use/technical manual Performance evaluation Pre-clinical evaluation Insurance certificate List of the Competent where protocol was submitted with their decision if available Copy of the required authorization ( authorisation de lieu de recherche )

Initial submission Standard application form available on the ANSM s website:

- Vigilance SAE definition: Any untoward medical occurrence or effect that at any dose: - Result in death - Is life threatening - Requires hospitalisation or prolongation of eisting hospitalisation - Results in persistent or significant disability or incapacity - Or is a congenital anomaly or birth defect SAE declaration by the sponsor: - If life in danger: 7 days - Other case: 15 days The sponsor has to declare events to the Competent Authorities in the specific countries The sponsor needs to provide to the Competent an annual safety report

- Vigilance H. Data Ptotection Events mandatory to declare to the Competent : Medical device alone with CE mark use within label Medical device alone with CE mark use outside label AE ADE SADE SAE Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device AE: Adverse Event (Non device related) ADE: Adverse Device Effect (Device or procedure related) SADE: Serious adverse Device Effect (Device or procedure related) SAE: Serious Adverse Event (Non device related)

- Vigilance The sponsor is responsible for the declaration to the Competent Special form for the declaration of AE:

- Notification It is not mandatory to notify the first patient enrolled to the Competent

Substantial amendment There is a specific procedure for submitting a substantial amendment to the Competent (Submission of a dossier and waiting for approval)

SECTIONS A.Type of research

40 Comités de Protection des Personnes (CPP) in France:

Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device Positive opinion required Yes No

Initial submission When a submission is required, the sponsor is responsible of it The submission to the Ethics Committee is local: you only have to submit one dossier to one of the regional Ethics Committee in the region of the Principal Investigator The submission have to be: - by paper (usually many copies) - and/or by email or CD-Rom English documents are accepted, at the eception of the protocol summary, the inform consent form, the information document for patient and additional document No submission fee

Initial submission H. Data Ptotection In general, 35-60 days to obtain approval No implicit approval Deadlines for submissions, once per month in each EC (different dates for each EC) When both Competent approval and Ethics Committee positive opinion are required, it is possible to request the 2 (authorization and approval) in parallel No need to have some kind of representative or a legal entity in France to submit an application to the Competent or Ethics Committee if you are from the EU

Initial submission H. Data Ptotection Main documents required for submission: Submission letter Clinical Trial application form Clinical Investigation Plan/Protocol Clinical Investigation Plan/Protocol summary Inform Consent Form and subject Information leaflet CV of PIs Copie of advertisement materials for research participant Investigator s brochure or CE certificate Instruction for use/technical manual Insurance certificate List of the CA where protocol was submitted with their decision if available Copy of the required authorization ( authorisation de lieu de recherche ) Additional document

G. Ethics committee Initial submission Use the same standard application form that for the Competent Standard application form available on the ANSM s website:

- Vigilance SAE declaration by the sponsor: - If life in danger: 7 days - Other case: 15 days The sponsor also has to declare events to the Ethics Committee in the specific countries The sponsor needs to provide to the Ethics Committee an annual safety report

- Vigilance Events mandatory to declare to the competent authority: Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device AE ADE SADE SAE AE: Adverse Event (Non device related) ADE: Adverse Device Effect (Device or procedure related) SADE: Serious adverse Device Effect (Device or procedure related) SAE: Serious Adverse Event (Non device related)

- Vigilance The sponsor is responsible for the declaration to the Ethics Committee No special form for the declaration of AE, possible to use the Competent s form:

- Notification It is not mandatory to notify the first patient enrolled to the Ethics Committee

Substantial amendment There is a specific procedure for submitting a substantial amendment to the Ethics Committee (Submission of a dossier and waiting for approval)

SECTIONS A.Type of research

H. Data Ptotection French Data Protection: CNIL (Commission Nationale de l Informatique et des Liberté) 8 rue vivienne 75083 Paris cede 02 Tel : +33 153 73 22 22 / Fa : +33 153 73 22 00

Medical device alone with CE mark use within label Medical device alone with CE mark use outside label Medical device alone without CE mark Medical device combined with medicinal product with CE mark use within label Medical device combined with medicinal product with CE mark use outside label Medical device combined with medicinal product without CE mark Observational studies with medical device Notification required Yes No

Submission in French only No submission fee Online submission

SECTIONS A.Type of research

H. Data Ptotection In France, there are specific /regulations for specific population: - Children - Pregnant women - Lactating women - Adults protected by the law

Healthy volunteers participating in clinical research have to be compensated (not mandatory for patients, but possible) National healthy volunteers registry: VRB Obligation to inform the healthy volunteers/patients on the outcomes of the study if she/he asks

SECTIONS A.Type of research

No specific to publish both positive and negative results of clinical studies in scientific journals Specific /regulations regarding the ICF: needs to be given in writing Specific /regulations regarding archiving of documentation: 15 years Specific regarding blood/tissue samples (circulation and storage) Additional forms to submit the Competent

No specific for data management No specific strategies for monitoring Mandatory to register clinical studies which include medicinal product in a registry managed by the Competent Accreditation process for research centres ( Code de santé publique article R1121-11 to article R1121-16)